Vosoritide

Vosoritide (brand name Vosoritide) is a synthetic peptide-based medicine used to treat achondroplasia, which is the most common form of dwarfism. It is a growth factor receptor (GFR) agonist, which means it stimulates bone growth. Vosoritide is administered as a subcutaneous injection and works by activating the GFR to promote bone growth in children and adults with achondroplasia. It is not a cure for achondroplasia, but it has been shown to improve height and reduce the risk of some complications associated with the condition.
 

Vosoritide is a medication that treats achondroplasia, a genetic disorder that affects bone growth in children. Here's a breakdown of its key aspects:

Condition:

• Vosoritide is specifically used to increase linear growth (height) in children with achondroplasia (ACH) [1, 2, 3]. This condition results in shortened limbs and disproportionate stature.

Mechanism of Action:

• It belongs to a class of drugs called C-type natriuretic peptide (CNP) analogs [1, 2]. CNP is a naturally occurring hormone that stimulates the growth of cartilage cells, which are precursors to bone. Vosoritide mimics the effects of CNP, promoting cartilage growth and ultimately leading to increased bone growth in the long bones of children with achondroplasia [2, 3].

Use:

• Vosoritide is administered as a daily injection, typically under the skin of the thigh or abdomen [2, 4].
• Treatment is most effective when given to children with open growth plates (areas of cartilage where bones can still grow longer) [3].